



ocket No.: 104322.198US1

PATENT/OFFICIAL

*lsu*  
*AF/1961*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Ravi V. J. CHARI

Serial No. 09/671,995

Filed: September 29, 2000

:  
:  
:  
:  
:  
:

Group Art Unit: 1642

Examiner: Karen A. Canella

For: COMPOSITIONS AND METHODS FOR TREATING CANCER USING  
IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Applicants' representative certifies that the enclosed documents were cited in a communication from the European Patent Office in a counterpart foreign application not more than three months before the filing date of this Information Disclosure Statement.

Serial No. 09/671,995

No fee is believed to be required, however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP



Belinda M. Lew  
Registration No. 53,212

1455 Pennsylvania Avenue, NW  
Washington, DC 20004

TEL 202.942.8400 BML/mgm

FAX 202.942.8484

Date: OCT. 12, 2009

INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.  
104322.198US1SERIAL NO.  
09/671,995APPLICANT  
Ravi V. J. CHARIFILING DATE  
September 29, 2000GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,208,020	05/04/93	Chari et al.			07/13/92
	5,416,064	05/16/95	Chari et al.			12/07/92
	5,679,648	10/21/97	McCaffrey et al.			11/30/94

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Gupta, Radhey, S. May 5, 1985. "Cross-Resistance of Vinblastine and Taxol-Resistant Mutants of Chinese Hamster Ovary Cells to Other Anticancer Drugs." <i>Cancer Treatment Reports</i> , Vol. 69, No. 5. pp. 515-521.
	Liu, Changnian and Ravi V. J. Chari. February 1997. "The development of antibody delivery systems to target cancer with highly potent maytansinoids." <i>Exp. Opin. Invest. Drugs</i> , Vol. 6, No. 2. pp. 169-172.
	Chari, Ravi V. J. et al. 1992. "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs." <i>Cancer Research, American Association for Cancer Research</i> , Vol. 52, No. 1. pp. 127-131.
	Nakajima, Osamu, Yasuko Sugishita, Yuichi Hashimoto and Shigeo Iwasaki. 1994. "Increase in the Chemically-Induced Differentiation of Human Leukemia Cell Lines by Tubulin Disruptors." <i>Biol. Pharm. Bull.</i> Vol. 17, No. 5. pp. 742-744.
	Liu, C., et al. "Cure of Large Human Colon Cancer Xenografts by a C242-Maytansinoid Conjugate." <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> , Vol. 37, No. 2. pp. 466 - 467.
	Jordan, Allan, John A. Hadfield, Nicholas J. Lawrence and Alan T. McGown. "Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle." <i>Medicinal Research Reviews</i> , Vol. 18, No. 4. pp. 259-296.
	12 July 2004. Supplementary Partial European Search Report from European Patent Application No. 00970516.1.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.